The ‘Kawasaki Disease Coronary Artery Aneurysm Prevention trial (KD-CAAP)’ study will be utilising the infrastructure and resources of the conect4children network.
Kawasaki disease is a disease where arteries, particularly the coronary arteries in the heart, become inflamed, sometimes causing irreversible heart damage, heart attacks or even death. To prevent heart damage, Kawasaki disease in children and young people must be recognised by clinicians early, and promptly treated with anti-inflammatory medicines. This study will assess the effectiveness of adding steroids to standard treatment in children with Kawasaki Disease, and aims to recruit 262 children as part of the study. The study will continue to open in approximately 60 sites in 15 countries across Europe.
The c4c research Consortium brings together pharmaceutical companies, paediatric national networks as well as EU multinational sub-speciality networks, large patient advocacy groups, children’s hospitals and other public research organisations from across Europe. The project consortium is a novel collaboration between academic and private sectors that include 33 academic and 10 industry partners from 20 European countries.
German c4c-Website: https://www.germannetpaet.de/